Evidence map›Paper›PMID 28407688›Full record

ArticleOncotarget2017

NPC-26 kills human colorectal cancer cells via activating AMPK signaling.

Zhen Zhao, Li Feng, Jiqin Wang, Deshan Cheng, Mei Liu, Meirong Ling, Weiping Xu, Keyu Sun

Abstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Targeting Mitochondrial Ion Channels to Fight Cancer.International journal of molecular sciences · 2018
    Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zhen ZhaoClinical Laboratory, Minhang Hospital, Fudan University, Shanghai, China.
Li FengDepartment of Gastroenterology, Minhang Hospital, Fudan University, Shanghai, China.
Jiqin WangEmergency Department, Minhang Hospital, Fudan University, Shanghai, China.
Deshan ChengEmergency Department, Minhang Hospital, Fudan University, Shanghai, China.
Mei LiuEmergency Department, Minhang Hospital, Fudan University, Shanghai, China.
Meirong LingEmergency Department, Minhang Hospital, Fudan University, Shanghai, China.
Weiping XuShanghai University of Medicine & Health Sciences, Shanghai, China.
Keyu SunEmergency Department, Minhang Hospital, Fudan University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

NPC-26 is novel mitochondrion-interfering compound. The current study tested its potential effect against colorectal cancer (CRC) cells. We demonstrated that NPC-26 induced potent anti-proliferative and cytotoxic activities against CRC cell lines (HCT-116, DLD-1 and HT-29). Activation of AMP-activated protein kinase (AMPK) signaling mediated NPC-26-induced CRC cell death. AMPKα1 shRNA knockdown or dominant negative mutation abolished NPC-26-induced AMPK activation and subsequent CRC cell death. NPC-26 disrupted mitochondrial function, causing mitochondrial permeability transition pore (mPTP) opening and reactive oxygen species (ROS) production. ROS scavengers (NAC or MnTBAP) and mPTP blockers (cyclosporin A or sanglifehrin A) blocked NPC-26-induced AMPK activation and attenuated CRC cell death. Significantly, intraperitoneal injection of NPC-26 potently inhibited HCT-116 tumor growth in severe combined immuno-deficient (SCID) mice. Yet, its anti-tumor activity was significantly weakened against AMPKα1-silenced HCT-116 tumors. Together, we conclude that NPC-26 kills CRC cells possibly via activating AMPK signaling.

Indexed as

AMP-Activated Protein KinasesAnimalsAntineoplastic AgentsColorectal NeoplasmsEnzyme ActivationHCT116 CellsHT29 CellsHumansMiceMice, SCIDSignal TransductionXenograft Model Antitumor AssaysAMP-Activated Protein KinasesAntineoplastic AgentsAMP-activated protein kinase (AMPK)cell deathcolorectal cancermitochondrionNPC-26

Identifiers

PMID28407688
PMCPMC5392330

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.